Lot-to-lot variation of unfractionated heparin using the anti-factor Xa assay.

被引：0
|
作者：
Pullen, GE
Siegel, JE
Goodell, LA
机构：
[1] Robert Wood Johnson Univ Hosp, New Brunswick, NJ USA
[2] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[3] Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Newark, NJ 07103 USA
来源：
AMERICAN JOURNAL OF CLINICAL PATHOLOGY | 2002年 / 118卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
95
引用
收藏
页码：648 / 649
页数：2
相关论文
共 50 条
  • [1] POPULATION PHARMACOKINETIC AND PHARMACODYNAMIC MODELING OF UNFRACTIONATED HEPARIN USING ANTI-FACTOR XA ASSAY IN PEDIATRIC PATIENTS.
    Niu, T.
    Li, C.
    Ivaturi, V.
    Moffett, B.
    Gopalakrishnan, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S94 - S94
  • [2] Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin
    Castro-Lopez, Vanessa
    Murray, Brian
    Harris, Leanne F.
    O'Donnell, James S.
    Killard, Anthony J.
    BLOOD COAGULATION & FIBRINOLYSIS, 2012, 23 (01) : 98 - 103
  • [3] Achievement of therapeutic anticoagulation with implementation of a new heparin dosing nomogram and monitoring with the anti-factor Xa assay.
    Benipal, Harpreet
    Gundrum, Todd E.
    Jung, Rose
    Murphy, Julie A.
    PHARMACOTHERAPY, 2014, 34 (10): : E205 - E205
  • [4] IMPACT OF TARGETED TEMPERATURE MANAGEMENT ON ANTI-FACTOR XA MONITORING OF UNFRACTIONATED HEPARIN
    Fedkiv, Volodymyra
    Oh, Song
    Bingham, Angela
    Delic, Justin
    Igneri, Lauren
    Hollands, James
    CRITICAL CARE MEDICINE, 2021, 49 (01) : 596 - 596
  • [5] Evaluation of lot-to-lot repeatability and effect of assay media choice in the recombinant Factor C assay
    McKenzie, Jennifer Helen
    Alwis, K. Udeni
    Sordillo, Joanne E.
    Kalluri, Kesava Srinivas
    Milton, Donald Kirby
    JOURNAL OF ENVIRONMENTAL MONITORING, 2011, 13 (06): : 1739 - 1745
  • [6] Anti-factor Xa assay versus aPTT for the monitoring of unfractionated heparin infusions in patients treated for cardiac indications
    Marston, Matthew, Jr.
    Heath, Emily
    Ford, Renee
    Griffin, Lukas
    Boudreau, Marybeth
    PHARMACOTHERAPY, 2013, 33 (10): : E190 - E191
  • [7] Automated anti-factor IIa assay for monitoring unfractionated heparin (UFH)
    Summerhayes, R.
    Ignjatovic, V
    Newall, F.
    Monagle, P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 : 1091 - 1091
  • [8] Lot-to-lot variation in anti-hepatitis C signal-to-cutoff ratio
    Dufour, DR
    CLINICAL CHEMISTRY, 2004, 50 (05) : 958 - 960
  • [9] Comparing Anti-Factor Xa and Activated Partial Thromboplastin Levels for Monitoring Unfractionated Heparin
    Wahking, Rebekah A.
    Hargreaves, Rachel H.
    Lockwood, Sean M.
    Haskell, Sabrina K.
    Davis, Kelly W.
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (08) : 801 - 805
  • [10] Lack of Inter-Laboratory Agreement in the Monitoring of Unfractionated Heparin Using the Anti-Factor Xa Activity and the Anti-Factor Xa-Correlated Activated Partial Thromboplastin Time
    Toulon, Pierre
    Smahi, Motalib
    De Pooter, Neila
    Zereg, Elamine
    BLOOD, 2017, 130
12345